



LamKap Bio

LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment

- LamKap Bio Group develops fully human bispecific $\kappa\lambda$ antibodies targeting malignant cells in solid cancers
- Lonza to provide cell line development, drug substance and drug product services and cGMP manufacturing for two programs
- Lonza's LightPath™ cell line development program was optimized to ensure improved process yield and throughput

Quote from Shiva Khalafpour, VP, Head of Commercial Mammalian and Microbial Development and Manufacturing, Lonza:

“Lonza's subject matter experts enjoyed working with LamKap's technical team to identify specific molecule needs and design a tailored work package suitable to achieve their goals. This included a customized cell line development program based on Lonza's GS Gene Expression System® and LightPath™ CLC methodology and optimization of the customer downstream purification approach in order to facilitate manufacturing.”

“Quote from Klaus Strein, Chairman of the LamKap Bio Group:

The LamKap Bio Group together with its strategic partner Light Chain Biosciences/NovImmune have considerable experience in the R&D of T-cell bispecific antibodies and tumor targeted anti-CD47 bispecific antibodies. Technical development and GMP manufacturing of both types of bispecific antibodies were already successfully performed by Lonza in the recent years. The new collaboration with Lonza is an important pillar in the development of two Clinical Leads.

Basel and Pfäffikon, Switzerland, 17 September 2020 – LamKap Bio Group, a biotechnology group focused on the research, development and manufacturing of tumor-targeted antibody-based therapies, and Lonza announced today that the companies have a development and manufacturing collaboration in place to support their current and future product pipeline. Lonza will provide cell line and process development, drug substance manufacturing and drug

product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.

LamKap's therapeutic bispecific antibodies are engineered to bind to two different antigens simultaneously. The two antigens can be either located on one cell type, e.g., a tumor cell, or two different cell types, e.g., on a tumor cell and an immune effector cell. Both NILK-2301 and NILK-2401 can be used as monotherapy and/or in combination. NILK-2301 binds to a tumor-associated antigen (TAA) and CD3 on T-cells, re-targeting T cells to kill tumor cells. NILK-2401 is also targeted to a TAA and in addition to CD47 on tumor cells, thus causing increased antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC).

Using LamKap's fully human bispecific Kappa Lambda antibodies ($\kappa\lambda$), consisting of two identical heavy chains, a kappa (κ) and a lambda (λ) light chain and an IgG1 Fc, helps the human body to fight cancer. This structure is nearly identical to the structure of a standard IgG antibody and lowers the risk of inducing immunogenicity while minimizing the loss of exposure. Antibodies in this format are ideally suited for therapeutic application in both benign and malignant diseases. The $\kappa\lambda$ format facilitates production/purification.

Building upon Lonza's previous experience with the $\kappa\lambda$ body program, as well as several other bispecific antibody platforms and the extensive upstream and downstream processing know-how, Lonza will carry out cell line construction and cGMP drug substance manufacturing at its Slough, UK and Hayward, US sites. The LightPath™ cell line development program will start in Q3 2020, providing LamKap with material to enter phase I clinical studies. The early-stage drug product formulation and stability studies will be performed at Lonza's Drug Product Services facility in Basel, Switzerland.

The scope of the package was tailored to ensure the program could meet the requirements of large-scale manufacturing of unique $\kappa\lambda$ body products.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

About LamKap Bio Group

The LamKap Bio Group researches, develops, and manufactures bispecific antibodies for the treatment of malignant tumors. We redirect the patient's own immune cells, especially macrophages, T-cells and natural killer cells, to attack cancer cells – helping the body to fight cancer

The LamKap Bio Group currently comprises three separate companies each dedicated to the development of a T cell or phagocytes and natural killer cells engaging bispecific antibody targeting a specific tumor-associated antigen. LamKap Bio alpha AG, LamKap Bio beta AG and LamKap Bio gamma AG are working independently on one or more bsAb projects.

Our team in the LamKap Bio Group combines long-term experience in highly successful Big Pharma and Biotech with clinical and scientific excellence in academia. Together we develop novel treatment options for cancer patients.

Find out more at www.lamkapbio.com

Lonza Contact Details

Dr. Sanna Fowler

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 8929

sanna.fowler@lonza.com

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 79 421 1609

dirk.oehlers@lonza.com

LamKap Bio Group Contact Details

Dr. Oliver Eckelmann

COO & CFO

LamKap Bio Group

Tel: +41 55 566 7502

oe@lamkapbio.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.